Novartis (NVS)
(Delayed Data from NYSE)
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar
by Zacks Equity Research
Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.
Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion
by Zacks Equity Research
Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca
by Zacks Equity Research
AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.
4 Large Drug Stocks to Watch as Fundamentals Stay Strong
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
Pharma Stock Roundup: FDA Authorization of Omicron Boosters, SNY's Xenpozyme & More
by Kinjel Shah
FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.
Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC
by Zacks Equity Research
Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.
Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre
by Zacks Equity Research
Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer
by Zacks Equity Research
Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.
Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why
by Zacks Equity Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
by Zacks Equity Research
Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
by Kinjel Shah
Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.
Novartis (NVS) Plans to Spin Off Generics Business Sandoz
by Zacks Equity Research
Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.
Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up
by Zacks Equity Research
Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
by Kinjel Shah
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
by Zacks Equity Research
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2
by Zacks Equity Research
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
by Zacks Equity Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
The Zacks Analyst Blog Highlights Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems
by Zacks Equity Research
Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems are part of Zacks top Analyst Blog.
Top Analyst Reports for Novartis, Duke Energy & Boston Scientific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Duke Energy Corporation (DUK), and Boston Scientific Corporation (BSX).
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.
The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie
by Zacks Equity Research
J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.